Ad copy

The stool panel your gastroenterologist ordered was the correct next step. The organisms driving long term IBS were not on the list it was built around. Most IBS patients are ordered a standard stool panel that screens for seven to twelve organisms. It was designed to identify the most common acute gastrointestinal pathogens. Salmonella. Campylobacter. E. coli. The organisms responsible for food poisoning and acute infection. It was not designed for what comes next. A comprehensive parasitology panel screens for more than thirty organisms. The gap between twelve and thirty is not a minor clinical footnote. It is where most long term IBS cases have been living for years without a diagnosis that goes beyond symptom management. The question worth asking is what specifically occupies that gap and why the standard panel was never built to find it. The answer has to do with how the standard diagnostic pathway was developed. The panel screens for acute infection organisms because acute infection was the clinical problem it was designed to solve. Chronic low grade intestinal disruption driven by organisms embedded in the mucosal lining was not part of that original design brief. Not because it is rare. Because it presents differently. It does not announce itself the way food poisoning does. It produces the kind of slow background dysfunction that dietary management can reduce enough to make it livable, which is exactly what makes it so easy to miss. What those organisms do when they embed in the mucosal lining is specific and consistent enough to be worth understanding directly. They produce a chronic localized inflammatory response at the tissue level. That inflammation disrupts the migrating motor complex, the gut's internal cleaning mechanism that operates between meals sweeping bacteria and debris through the small intestine. When the migrating motor complex is impaired bacteria accumulate between meals regardless of what is eaten. That accumulation ferments available substrate. The fermentation produces the gas, bloating, and urgency that low FODMAP reduces by limiting how much fermentable substrate is available. Which means the protocol is working exactly as designed. It is reducing the consequence of something it was never designed to find. Search "parasitic organisms migrating motor complex IBS" to verify what that clinical connection looks like in the literature. The research exists. It simply has not made its way into the standard diagnostic conversation most IBS patients are offered. And it raises an obvious question. If identifying the cause is possible, why has treating it been so difficult. The antiparasitics available address adult organisms only. The egg stage, embedded in the intestinal wall inside a lipid based shell that water soluble pharmaceutical compounds cannot penetrate, survives every course of treatment. The adults die. Three to four weeks later the eggs hatch undisturbed. New adults mature. The inflammatory response at the mucosal lining rebuilds. The migrating motor complex remains impaired. FODMAP remains necessary. The cycle continues not because the treatment failed but because it was only ever reaching half the problem. The compound with documented capacity to cross the parasite eggshell lipid barrier is called Eugenol. Found in raw clove, lipid soluble at the molecular level, capable of crossing the outer shell of a parasite egg from the outside before the developmental program triggers hatching. In theory this changes everything. In practice there is a manufacturing problem that disqualifies almost every clove containing product on the market. Eugenol is destroyed by heat. Nearly every supplement manufacturer uses heat in their extraction process because it is faster and cheaper. For Eugenol this is complete destruction. The clove is listed accurately on the label. The active compound is gone before the bottle is sealed. Which means finding a formulation that actually preserved it required a different extraction method entirely. Cold pressing uses slow mechanical pressure on raw botanical material with no heat and no solvents. The active compounds arrive intact. Almost no manufacturer invests in it because the equipment is expensive and production volume is small. The formulation that does it correctly and delivers sublingually so the Eugenol reaches the intestinal wall through circulation rather than depending on a compromised gut to absorb it is called ParaCycle. A liquid tincture. Two drops under the tongue each morning. Every batch third party laboratory verified. No fillers. When the organisms embedded in the mucosal lining are addressed at the egg stage for the first time, the inflammatory disruption to the migrating motor complex resolves. The gut's internal cleaning mechanism resumes function. Bacterial accumulation between meals normalizes. The dietary management that was controlling the consequence of the diagnostic gap stops being necessary because what was causing the gap has finally been reached. ParaCycle offers a 60 day guarantee, empty bottle included. If the results are not there after a full protocol, send it back. Small batches. Cold pressing does not scale the way heat extraction does which means inventory moves quickly. Check availability below. The panel your doctor ordered was not wrong. It just was not looking for what was actually there. Now something is.